• 1
    Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:21742.
  • 2
    Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:1217.
  • 3
    Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2:95101.
  • 4
    Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002; 13:14354.
  • 5
    Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2:10815.
  • 6
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette–Guérin immunotherapy of superficial bladder cancer. J Urol 1980; 124:3840.
  • 7
    O'Donnell MA, DeWolf DC. Bacillus Calmette–Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995; 4:189202.
  • 8
    Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:168994.
  • 9
    Ratliff TL. Bacillus Calmette–Guerin (BCG): mechanism of action in superficial bladder cancer. Urology 1991; 37 (5 Suppl.):811.
  • 10
    Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette–Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144:538.
  • 11
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147:163642.
  • 12
    Peuchmaur M, Benoit G, Vieillefond A et al. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette–Guérin. Urol Res 1989; 17:299303.
  • 13
    Saint F, Patard JJ, Groux Muscatelli B et al. Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette–Guérin treatment. BJU Int 2001; 88:60210.
  • 14
    De Boer EC, De Jong WH, Van Der Meijden AP et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette–Guérin. Cancer Immunol Immunother 1991; 33:41116.
  • 15
    De Boer EC, De Jong WH, Van Der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991; 19:4550.
  • 16
    De Boer EC, De Jong WH, Steerenberg PA et al. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette–Guérin. In Vivo 1991; 5:6717.
  • 17
    Bohle A, Nowc C, Ulmer AJ et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette–Guérin immunotherapy. J Urol 1990; 144:5964.
  • 18
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette–Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155:47782.
  • 19
    Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette–Guérin treatment for superficial bladder cancer. J Urol 2002; 167:3647.
  • 20
    Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette–Guérin. J Urol 2000; 164:212933.
  • 21
    Poppas DP, Pavlovich CP, Folkman J et al. Intravesical bacille Calmette–Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998; 52:26875.
  • 22
    Pavlovich CP, Kraling BM, Stewart RJ et al. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 2000; 163:201421.
  • 23
    Sanchez-Carbayo M, Urrutia M, Romani R et al. Serial urinary IL-2, IL-6, IL-8, TNF-alpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res 2001; 21:30417.
  • 24
    Kumar A, Dubey D, Bansal P, Mandhani A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette–Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002; 168:22325.
  • 25
    Saint F, Patard JJ, Maille P et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette–Guerin for superficial bladder cancer. J Urol 2001; 166:21427.
  • 26
    Nadler R, Luo Y, Zhao W et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette–Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131:20616.
  • 27
    O'Donnell MA, Aldovini A, Duda RB et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62:250814.
  • 28
    Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette–Guerin immunotherapy. J Immunol 1999; 162:2399405.
  • 29
    O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette–Guerin. J Immunol 1999; 163:424652.
  • 30
    De Reijke TM, Vos PC, De Boer EC et al. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette–Guerin (BCG). Urol Res 1993; 21:34952.
  • 31
    Bevers RF, De Boer EC, Kurth KH, Schamhart DH. Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette–Guerin. Br J Urol 1997; 80:359.
  • 32
    Bevers RF, De Boer EC, Kurth KH, Schamhart DH. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 1998; 9:1816.
  • 33
    Esuvaranathan K, Alexandroff AB, McIntyre M et al. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 1995; 154:5725.
  • 34
    Reale M, Intorno R, Tenaglia R et al. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette–Guerin immunotherapy. Cancer Immunol Immunother 2002; 51:918.
  • 35
    Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P. Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha. Urology 2006; 67:21419.
  • 36
    Bouchelouche K, Andresen L, Alvarez S, Nordling J, Nielsen OH, Bouchelouche P. Interleukin-4 and 13 induce the expression and release of monocyte chemoattractant protein 1, interleukin-6 and stem cell factor from human detrusor smooth muscle cells: synergy with interleukin-1beta and tumor necrosis factor-alpha. J Urol 2006; 175:7605.
  • 37
    Bouchelouche K, Alvarez S, Andersen L, Nordling J, Horn T, Bouchelouche P. Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells. J Urol 2004; 171:4626.
  • 38
    Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette–Guerin and interferon-alpha-2B on human bladder cancer in vitro. Int J Cancer 1997; 71:8517.
  • 39
    Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette–Guerin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 1999; 161:97783.
  • 40
    Thèze J. The cytokine network and immune functions. Oxford: Oxford University Press, 1999.
  • 41
    Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999; 20:2547.
  • 42
    Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000; 95:303243.
  • 43
    Godiska R, Chantry D, Raport CJ et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185:1595604.
  • 44
    Miyamasu M, Nakajima T, Misaki Y et al. Dermal fibroblasts represent a potent major source of human eotaxin: in vitro production and cytokine-mediated regulation. Cytokine 1999; 11:7518.
  • 45
    Schaefer D, Meyer JE, Pods R et al. Endothelial and epithelial expression of eotaxin-2 (CCL24) in nasal polyps. Int Arch Allergy Immunol 2006; 140:20514.
  • 46
    Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91:60712.